Factors Affecting the Adherence to Disease-Modifying Therapy in Patients With Multiple Sclerosis

被引:4
|
作者
von Gaudecker, Jane R. [1 ]
机构
[1] Indiana Univ, Sch Nursing, Indianapolis, IN 46204 USA
关键词
coping; fatigue; medication adherence; multiple sclerosis; nursing; self-efficacy;
D O I
10.1097/JNN.0000000000000405
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Adherence to medication treatment in patients with multiple sclerosis (MS) is important to increase its effectiveness, reduce patient disability, prevent attacks, and increase the quality of life. Aim: This study investigated factors that influence adherence to disease-modifying therapy in patients with MS. Methods: This descriptive study was conducted with 198 patients with MS who met the inclusion criteria and agreed to participate between July 2016 and February 2017. Data were collected using an Individual Identification Form that included sociodemographic characteristics, the Multiple Sclerosis Treatment Adherence Questionnaire, the Fatigue Severity Scale, the Self-Efficacy Scale, and the Brief COPE. Results: We found that 59.6% of the patients were adherent to therapy. Patients were significantly more adherent to Avonex than other treatments, and memory problems was the most common reason for missing or forgetting medication in nonadherent patients. There was a significant difference between medication adherence and some sociodemographic characteristics and disease characteristics (P < .05). There was no significant difference between coping attitudes, fatigue, and self-efficacy level and medication adherence (P > .05). Conclusion: Patients' adherence to medication treatment was low and may be associated with social, physical, and cognitive measures.
引用
收藏
页码:302 / 302
页数:1
相关论文
共 50 条
  • [41] Disease-Modifying Therapy in Multiple Sclerosis: Evaluation of Patients Satisfaction in Iranian Multiple Sclerosis Population
    Molazadeh, Negar
    Sahraian, Mohammad Ali
    Ghajarzadeh, Mahsa
    CASPIAN JOURNAL OF INTERNAL MEDICINE, 2023, 14 (01) : 89 - 93
  • [42] Disease-modifying therapy aids cognition in multiple sclerosis
    Amato, Maria Pia
    Krupp, Lauren B.
    NATURE REVIEWS NEUROLOGY, 2020, 16 (10) : 525 - 526
  • [43] Vitamin D as disease-modifying therapy for multiple sclerosis?
    Lincoln, Matthew R.
    Schneider, Raphael
    Oh, Jiwon
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2021, 17 (07) : 691 - 693
  • [44] Multiple sclerosis Diagnosis, disease-modifying therapy and prognosis
    Travers, Brett S.
    Tsang, Benjamin K-T
    Barton, Joshua L.
    AUSTRALIAN JOURNAL OF GENERAL PRACTICE, 2022, 51 (04) : 199 - 206
  • [45] Breastfeeding and Disease-Modifying Therapy for Multiple Sclerosis Reply
    Hellwig, Kerstin
    Langer-Gould, Annette M.
    JAMA NEUROLOGY, 2016, 73 (04) : 480 - 481
  • [46] Disease-modifying therapy aids cognition in multiple sclerosis
    Maria Pia Amato
    Lauren B. Krupp
    Nature Reviews Neurology, 2020, 16 : 525 - 526
  • [47] Narrative Review of the Literature on Adherence to Disease-Modifying Therapies Among Patients with Multiple Sclerosis
    Menzin, Joseph
    Caon, Christina
    Nichols, Christine
    White, Leigh Ann
    Friedman, Mark
    Pill, Michael W.
    JOURNAL OF MANAGED CARE PHARMACY, 2013, 19 (01): : S24 - S40
  • [48] A pilot study of psychological factors affecting adherence to disease modifying treatments for multiple sclerosis
    Gray, N.
    Dickson, T.
    Neumann, C.
    McIndoe, N.
    Gaylor, H.
    O'Carroll, R.
    PSYCHOLOGY & HEALTH, 2009, 24 : 192 - 193
  • [49] Use of an Early Disease-Modifying Drug Adherence Measure to Predict Future Adherence in Patients with Multiple Sclerosis
    Kozma, Chris M.
    Phillips, Amy L.
    Meletiche, Dennis M.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2014, 20 (08): : 800 - 807
  • [50] Association between multiple sclerosis disease severity and adherence to disease-modifying therapies
    Burkhard, Adam
    Toliver, Joshua
    Rascati, Karen
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (07): : 915 - 923